Form 4: AN2 Therapeutics Director Melvin Spigelman Granted 19,111 Stock Options

AN2 Therapeutics, Inc. Director Melvin K. Spigelman was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

Summary

• Melvin K. Spigelman, a Director of AN2 Therapeutics, Inc. (ANTX), was granted 19,111 stock options.
• The options have an exercise price of $1.19 per share.
• These options were granted on May 22, 2025.
• The options will vest on March 31, 2026, contingent on Mr. Spigelman's continuous service through that date.
• The options have an expiration date of May 21, 2035.
• Following this transaction, Mr. Spigelman directly beneficially owns 19,111 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal as it aligns management interests with shareholder value. It's a routine compensation event, so the sentiment is moderately positive rather than highly impactful on its own.

Positives

• The granting of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The exercise price of $1.19 provides a clear benchmark for future stock performance relative to the grant date, indicating a potential upside for the director if the stock price increases.

Risks

• The vesting of the options is contingent upon the reporting person providing continuous service through March 31, 2026, meaning the options could be forfeited if service is terminated before this date.
• The ultimate value of the options is dependent on the future market price of AN2 Therapeutics' common stock exceeding the exercise price of $1.19; if the stock price remains below this, the options may hold no intrinsic value.

Future Outlook

The stock options are set to vest on March 31, 2026, contingent on the director's continuous service, providing a future incentive for performance. The options have a long expiration date of May 21, 2035, allowing for long-term value realization based on the company's future stock performance.

Industry Context

Stock option grants to directors are a common form of executive and board compensation in the biotechnology and pharmaceutical industries, aiming to align leadership interests with long-term shareholder value creation. This practice is standard across publicly traded companies, particularly those in growth-oriented sectors like biotech, where equity incentives are crucial for attracting and retaining talent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice in the U.S. public company landscape, particularly for early-stage or growth companies in the biotech sector like AN2 Therapeutics.
• The vesting schedule, tied to continuous service, is typical for equity compensation designed to retain key personnel and align their interests with long-term company performance.
• The exercise price being set at a specific value ($1.19) is common for options, often reflecting the stock price at or around the grant date.
• While specific comparable companies or projects are not mentioned in the filing, this type of compensation structure is widely observed across biotech firms of similar market capitalization and development stage, such as those focused on novel therapeutic development.

Related Party Transactions

• The grant of 19,111 stock options to Melvin K. Spigelman, a Director of AN2 Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. Future exercise of options could lead to minor dilution.
• Management: The director is incentivized to contribute to the company's success and long-term value creation.
• Employees: While not directly impacted, it reinforces the company's use of equity compensation as a retention and incentive tool.

Next Steps

• Melvin K. Spigelman's continuous service through March 31, 2026, is required for the options to vest.
• Potential exercise of the stock options by Melvin K. Spigelman at any time after vesting and before the expiration date of May 21, 2035.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, ANTX, Stock Option, Director Compensation, SEC Form 4, Insider Trading, Melvin K. Spigelman, Equity Grant, Vesting